Mindpeak, a leader in AI-powered pathology solutions, recently secured $15.3 million in Series A funding. The funding round was led by ZEISS Ventures and InnoVentureFund, with additional support from AI.FUND and the European Innovation Council Fund. Despite having a cash-flow positive core business, this fresh capital injection will allow Mindpeak to expand the commercialization of its innovative AI technologies globally.
“Our goal is to transform cancer diagnostics and ultimately improve patient outcomes,” said Felix Faber, CEO of Mindpeak. With the new funding, the company aims to accelerate the development and deployment of its AI-driven diagnostic tools, empowering pathologists and researchers to make faster and more accurate diagnoses.
Founded in 2018, Mindpeak is at the forefront of digital pathology, offering AI algorithms that assist with histological and immunohistochemical tissue analysis. Their technology is used not only by clinical labs but also by biopharma companies to help predict how effective certain cancer therapies might be. So far, Mindpeak’s solutions have contributed to over 30,000 patient diagnoses. The company has also expanded its offerings to cover additional organs, biomarkers, and stainings, building partnerships with healthcare giants like Roche.
ZEISS Ventures, the lead investor, praised Mindpeak’s potential. “Since its inception, Mindpeak has been a trailblazer in digital pathology,” said Mike Gänßler, Investment Manager at ZEISS Ventures. “We’re excited to see them continue to innovate in the field of cancer diagnostics.”
Likewise, Gencer Sahin, Head of Investments at IFB Innovationsstarter GmbH / InnoVentureFund, highlighted the company’s commitment to innovation, noting that the funding will solidify Mindpeak’s position as a key player in transforming cancer diagnostics globally.